Collaboration Agreements and Related Revenue Matters (Tables)

12 Months Ended

Jun. 30, 2020

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Summary of Associated Performance Obligations and Allocated Transaction Prices Upon The Initial Application of Topic 606

The associated performance obligations and allocated transaction prices upon the initial application of Topic 606 on July 1, 2018 are summarized in the table below.

In thousands
XLRS License and Pre-Funded Activities	$	52,060
XLRP License and Pre-Funded Activities		43,570
Pre-Funded Activities associated with the discovery programs		16,700
Total Biogen transaction price	$	112,330

Components of Collaboration Revenue

The table below summarizes the Company’s revenue related to the Biogen collaborative agreement for the year ended June 30, 2019. No Biogen collaboration revenue was recognized during the year ended June 30, 2020.

In thousands
Collaboration revenue
Licenses and related services	$	27,000
Development services		2,736
Milestone revenue		11,392
Total collaboration revenue	$	41,128

Summary of Changes in Contract Assets and Contract Liabilities

The table below summarizes changes in the balances of our contract assets and liabilities during the year ended June 30, 2019.

In thousands	June 30, 2018		Additions		Deletions			June 30, 2019
Contract assets	$	—	$	—	$	—		$	—
Contract liabilities:
Deferred revenue	$	29,521	$	10,000	$	(39,521	)	$	—